John Ervin
Rheumatology · Kansas City, MONPI 1376565549
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,935 of the $2,211 with a category attached, or 87.5%. AstraZeneca accounts for 98.4% of it on its own, with 1 other manufacturer making up the rest.
Across 9 payments — averaging $245.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Merck$35
Across 3,570 payments — averaging $5284.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Emergent Biosolutions Inc.$3.3M
- Merck$2.1M
- Johnson & Johnson$2.1M
- Valneva Austria GmbH$2M
- Sanofi Pasteur Inc.$1.9M
- Modernatx, Inc.$1.5M
- plus $5.9M from 26 others
What the payments were for
- Travel & lodging$1,93588%
- Food & beverage$27612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $2,176 |
| Merck | 1 | $35 |
How this compares
$2,211 in reported general payments places this provider in the 55th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Kansas City
- Mark BoxKansas City$304K
- Ghaith NoaisehKansas City$69K
- Thomas ScottKansas City$48K
- Tina ShahKansas City$36K
- David JohnKansas City$3K
- Julian MagadanKansas City$3K
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Sona KamatSaint Louis$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.